ESR1 and breast cancer: ER loss occurs in a minority of ER + breast cancer through the course of therapy, is associated with ET resistance, and remains an important predictor of CDK4/6 inhibitor and ET efficacy (Finn et al., 2020; Griffiths et al., 2021).